A phase 1 trial evaluating HWK-206 in small cell lung cancer and neuroendocrine neoplasms
Latest Information Update: 06 Apr 2025
At a glance
- Drugs HWK-206 (Primary)
- Indications Neuroendocrine tumours; Small cell lung cancer
- Focus Adverse reactions
- 06 Apr 2025 New trial record
- 18 Mar 2025 According to Aadi Bioscience media release, the Phase 1 trial is planned in small-cell lung cancer and neuroendocrine neoplasms, where there are limited treatment options.